Apellis Pharmaceuticals
APLS
APLS
280 hedge funds and large institutions have $7.28B invested in Apellis Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 106 increasing their positions, 78 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
15% more funds holding
Funds holding: 243 → 280 (+37)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
5.53% more ownership
Funds ownership: 90.88% → 96.41% (+5.5%)
Holders
280
Holding in Top 10
13
Calls
$182M
Puts
$106M
Top Buyers
| 1 | +$108M | |
| 2 | +$106M | |
| 3 | +$52.5M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$40M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.4M |
Top Sellers
| 1 | -$31.7M | |
| 2 | -$28.4M | |
| 3 | -$27.7M | |
| 4 |
Goldman Sachs
New York
|
-$23M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$20.1M |